Huntington's disease: A randomized, controlled trial using the NMDA-antagonist amantadine

L. Verhagen Metman, M. J. Morris, C. Farmer, M. Gillespie, K. Mosby, Joanne Wuu, T. N. Chase

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

Objective: To examine the acute effects of the NMDA receptor antagonist amantadine on motor and cognitive function in Huntington's disease (HD). Background: Chorea in HD and in the levodopa-induced dyskinesias of PD may be clinically indistinguishable. In PD, hyperphosphorylation of NMDA receptors expressed on striatal medium spiny neurons contributes to peak-dose dyskinesias, and drugs that block these receptors can diminish chorea severity. Because these spiny neurons are the primary target of the neurodegenerative process in HD, sensitization of NMDA receptors on residual striatal neurons might also participate in the generation of motor dysfunction in HD. Methods: To evaluate this possibility, 24 patients with HD entered a double-blind placebo-controlled crossover study of amantadine with two 2-week arms. Results: Chorea scores were lower with amantadine (usually 400 mg/d) than placebo, with a median reduction in extremity chorea at rest of 36% (p = 0.04) for all 22 evaluable patients and of 56% in the 10 individuals with the highest plasma drug levels. Improvement correlated with plasma amantadine concentrations (p = 0.01) but not CAG repeat length. Parkinsonian rating scores did not worsen and there was no consistent change in cognitive measures. Adverse event profile was benign. Conclusions: Results suggest that NMDA receptor supersensitivity may contribute to the clinical expression of choreiform dyskinesias in HD and that selective antagonists at that site can safely confer palliative benefit.

Original languageEnglish
Pages (from-to)694-699
Number of pages6
JournalNeurology
Volume59
Issue number5
StatePublished - Sep 10 2002
Externally publishedYes

Fingerprint

Amantadine
Huntington Disease
N-Methylaspartate
Chorea
Randomized Controlled Trials
N-Methyl-D-Aspartate Receptors
Dyskinesias
Corpus Striatum
Neurons
Placebos
Drug Receptors
Levodopa
Cross-Over Studies
Cognition
Arm
Extremities
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Metman, L. V., Morris, M. J., Farmer, C., Gillespie, M., Mosby, K., Wuu, J., & Chase, T. N. (2002). Huntington's disease: A randomized, controlled trial using the NMDA-antagonist amantadine. Neurology, 59(5), 694-699.

Huntington's disease : A randomized, controlled trial using the NMDA-antagonist amantadine. / Metman, L. Verhagen; Morris, M. J.; Farmer, C.; Gillespie, M.; Mosby, K.; Wuu, Joanne; Chase, T. N.

In: Neurology, Vol. 59, No. 5, 10.09.2002, p. 694-699.

Research output: Contribution to journalArticle

Metman, LV, Morris, MJ, Farmer, C, Gillespie, M, Mosby, K, Wuu, J & Chase, TN 2002, 'Huntington's disease: A randomized, controlled trial using the NMDA-antagonist amantadine', Neurology, vol. 59, no. 5, pp. 694-699.
Metman LV, Morris MJ, Farmer C, Gillespie M, Mosby K, Wuu J et al. Huntington's disease: A randomized, controlled trial using the NMDA-antagonist amantadine. Neurology. 2002 Sep 10;59(5):694-699.
Metman, L. Verhagen ; Morris, M. J. ; Farmer, C. ; Gillespie, M. ; Mosby, K. ; Wuu, Joanne ; Chase, T. N. / Huntington's disease : A randomized, controlled trial using the NMDA-antagonist amantadine. In: Neurology. 2002 ; Vol. 59, No. 5. pp. 694-699.
@article{e48aad9d6f494a3ab3f254709b893859,
title = "Huntington's disease: A randomized, controlled trial using the NMDA-antagonist amantadine",
abstract = "Objective: To examine the acute effects of the NMDA receptor antagonist amantadine on motor and cognitive function in Huntington's disease (HD). Background: Chorea in HD and in the levodopa-induced dyskinesias of PD may be clinically indistinguishable. In PD, hyperphosphorylation of NMDA receptors expressed on striatal medium spiny neurons contributes to peak-dose dyskinesias, and drugs that block these receptors can diminish chorea severity. Because these spiny neurons are the primary target of the neurodegenerative process in HD, sensitization of NMDA receptors on residual striatal neurons might also participate in the generation of motor dysfunction in HD. Methods: To evaluate this possibility, 24 patients with HD entered a double-blind placebo-controlled crossover study of amantadine with two 2-week arms. Results: Chorea scores were lower with amantadine (usually 400 mg/d) than placebo, with a median reduction in extremity chorea at rest of 36{\%} (p = 0.04) for all 22 evaluable patients and of 56{\%} in the 10 individuals with the highest plasma drug levels. Improvement correlated with plasma amantadine concentrations (p = 0.01) but not CAG repeat length. Parkinsonian rating scores did not worsen and there was no consistent change in cognitive measures. Adverse event profile was benign. Conclusions: Results suggest that NMDA receptor supersensitivity may contribute to the clinical expression of choreiform dyskinesias in HD and that selective antagonists at that site can safely confer palliative benefit.",
author = "Metman, {L. Verhagen} and Morris, {M. J.} and C. Farmer and M. Gillespie and K. Mosby and Joanne Wuu and Chase, {T. N.}",
year = "2002",
month = "9",
day = "10",
language = "English",
volume = "59",
pages = "694--699",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Huntington's disease

T2 - A randomized, controlled trial using the NMDA-antagonist amantadine

AU - Metman, L. Verhagen

AU - Morris, M. J.

AU - Farmer, C.

AU - Gillespie, M.

AU - Mosby, K.

AU - Wuu, Joanne

AU - Chase, T. N.

PY - 2002/9/10

Y1 - 2002/9/10

N2 - Objective: To examine the acute effects of the NMDA receptor antagonist amantadine on motor and cognitive function in Huntington's disease (HD). Background: Chorea in HD and in the levodopa-induced dyskinesias of PD may be clinically indistinguishable. In PD, hyperphosphorylation of NMDA receptors expressed on striatal medium spiny neurons contributes to peak-dose dyskinesias, and drugs that block these receptors can diminish chorea severity. Because these spiny neurons are the primary target of the neurodegenerative process in HD, sensitization of NMDA receptors on residual striatal neurons might also participate in the generation of motor dysfunction in HD. Methods: To evaluate this possibility, 24 patients with HD entered a double-blind placebo-controlled crossover study of amantadine with two 2-week arms. Results: Chorea scores were lower with amantadine (usually 400 mg/d) than placebo, with a median reduction in extremity chorea at rest of 36% (p = 0.04) for all 22 evaluable patients and of 56% in the 10 individuals with the highest plasma drug levels. Improvement correlated with plasma amantadine concentrations (p = 0.01) but not CAG repeat length. Parkinsonian rating scores did not worsen and there was no consistent change in cognitive measures. Adverse event profile was benign. Conclusions: Results suggest that NMDA receptor supersensitivity may contribute to the clinical expression of choreiform dyskinesias in HD and that selective antagonists at that site can safely confer palliative benefit.

AB - Objective: To examine the acute effects of the NMDA receptor antagonist amantadine on motor and cognitive function in Huntington's disease (HD). Background: Chorea in HD and in the levodopa-induced dyskinesias of PD may be clinically indistinguishable. In PD, hyperphosphorylation of NMDA receptors expressed on striatal medium spiny neurons contributes to peak-dose dyskinesias, and drugs that block these receptors can diminish chorea severity. Because these spiny neurons are the primary target of the neurodegenerative process in HD, sensitization of NMDA receptors on residual striatal neurons might also participate in the generation of motor dysfunction in HD. Methods: To evaluate this possibility, 24 patients with HD entered a double-blind placebo-controlled crossover study of amantadine with two 2-week arms. Results: Chorea scores were lower with amantadine (usually 400 mg/d) than placebo, with a median reduction in extremity chorea at rest of 36% (p = 0.04) for all 22 evaluable patients and of 56% in the 10 individuals with the highest plasma drug levels. Improvement correlated with plasma amantadine concentrations (p = 0.01) but not CAG repeat length. Parkinsonian rating scores did not worsen and there was no consistent change in cognitive measures. Adverse event profile was benign. Conclusions: Results suggest that NMDA receptor supersensitivity may contribute to the clinical expression of choreiform dyskinesias in HD and that selective antagonists at that site can safely confer palliative benefit.

UR - http://www.scopus.com/inward/record.url?scp=0037056392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037056392&partnerID=8YFLogxK

M3 - Article

C2 - 12221159

AN - SCOPUS:0037056392

VL - 59

SP - 694

EP - 699

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 5

ER -